JP3596835B2 - Hair restorer - Google Patents
Hair restorer Download PDFInfo
- Publication number
- JP3596835B2 JP3596835B2 JP23260996A JP23260996A JP3596835B2 JP 3596835 B2 JP3596835 B2 JP 3596835B2 JP 23260996 A JP23260996 A JP 23260996A JP 23260996 A JP23260996 A JP 23260996A JP 3596835 B2 JP3596835 B2 JP 3596835B2
- Authority
- JP
- Japan
- Prior art keywords
- hair
- extract
- growth
- hair growth
- hair restorer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004209 hair Anatomy 0.000 title claims description 36
- 230000003779 hair growth Effects 0.000 claims description 59
- 239000000284 extract Substances 0.000 claims description 26
- 239000000232 Lipid Bilayer Substances 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 18
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 10
- 229960003632 minoxidil Drugs 0.000 claims description 10
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 244000025221 Humulus lupulus Species 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- 241000086254 Arnica montana Species 0.000 claims description 4
- 235000008694 Humulus lupulus Nutrition 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- 244000246386 Mentha pulegium Species 0.000 claims description 4
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000001050 hortel pimenta Nutrition 0.000 claims description 4
- KVWWIYGFBYDJQC-UHFFFAOYSA-N methyl dihydrojasmonate Chemical compound CCCCCC1C(CC(=O)OC)CCC1=O KVWWIYGFBYDJQC-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000001296 salvia officinalis l. Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- -1 unsaturated aliphatic alcohols Chemical class 0.000 claims description 4
- 229920003169 water-soluble polymer Polymers 0.000 claims description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 3
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 claims description 3
- YCIXWYOBMVNGTB-UHFFFAOYSA-N 3-methyl-2-pentylcyclopent-2-en-1-one Chemical compound CCCCCC1=C(C)CCC1=O YCIXWYOBMVNGTB-UHFFFAOYSA-N 0.000 claims description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 3
- 239000004378 Glycyrrhizin Substances 0.000 claims description 3
- XMLSXPIVAXONDL-PLNGDYQASA-N Jasmone Chemical compound CC\C=C/CC1=C(C)CCC1=O XMLSXPIVAXONDL-PLNGDYQASA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 3
- 240000002657 Thymus vulgaris Species 0.000 claims description 3
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 3
- IVLCENBZDYVJPA-ARJAWSKDSA-N cis-Jasmone Natural products C\C=C/CC1=C(C)CCC1=O IVLCENBZDYVJPA-ARJAWSKDSA-N 0.000 claims description 3
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 3
- 229960000978 cyproterone acetate Drugs 0.000 claims description 3
- 229930182833 estradiol Natural products 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 claims description 3
- 229960003399 estrone Drugs 0.000 claims description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 3
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229960003136 leucine Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 3
- 229960002256 spironolactone Drugs 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- XMLSXPIVAXONDL-UHFFFAOYSA-N trans-jasmone Natural products CCC=CCC1=C(C)CCC1=O XMLSXPIVAXONDL-UHFFFAOYSA-N 0.000 claims description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
- 240000005979 Hordeum vulgare Species 0.000 claims description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 2
- 241000782597 Hypericum erectum Species 0.000 claims description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- 235000019766 L-Lysine Nutrition 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 229930182844 L-isoleucine Natural products 0.000 claims description 2
- 239000004395 L-leucine Substances 0.000 claims description 2
- 235000019454 L-leucine Nutrition 0.000 claims description 2
- 229930182821 L-proline Natural products 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 235000018978 Mentha arvensis Nutrition 0.000 claims description 2
- 240000007707 Mentha arvensis Species 0.000 claims description 2
- 241001479543 Mentha x piperita Species 0.000 claims description 2
- 240000007164 Salvia officinalis Species 0.000 claims description 2
- 235000002912 Salvia officinalis Nutrition 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- 239000001771 mentha piperita Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 claims description 2
- 235000002020 sage Nutrition 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- WKQCPUMQBMFPLC-ZWFCQKKLSA-N 11beta,21-Dihydroxypregn-4-ene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O WKQCPUMQBMFPLC-ZWFCQKKLSA-N 0.000 claims 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 claims 1
- 241000546188 Hypericum Species 0.000 claims 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 210000004761 scalp Anatomy 0.000 description 11
- 239000002502 liposome Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 201000004384 Alopecia Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940098465 tincture Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000003813 thin hair Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 2
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010070835 Skin sensitisation Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000370 skin sensitisation Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AKHONHCNYRUTLT-NXBFSHDWSA-N (8R,9S,10R,13S,14S,17S)-15,15,17-trihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4(O)O)O)[C@@H]4[C@@H]3CCC2=C1 AKHONHCNYRUTLT-NXBFSHDWSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OQZGLXOADHKTDN-UHFFFAOYSA-N 1-oxidopyrimidin-1-ium Chemical compound [O-][N+]1=CC=CN=C1 OQZGLXOADHKTDN-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 108090000474 3-oxo-5-alpha-steroid 4-dehydrogenase (NADP(+)) Proteins 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241001529742 Rosmarinus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 108010082150 estrone reductase Proteins 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940095585 testosterone-5-alpha reductase inhibitors for benign prostatic hypertrophy Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、良好な保水性を有して頭皮に水分を補給し、或いは頭皮からの水分蒸散を制御するとともに、育毛,養毛効果を有する成分を選択的且つ効率よく毛包に到達させることにより、頭皮を乾燥から保護して頭皮の乾燥に起因するふけ,痒み等の症状を緩和し、且つ非常に優れた育毛,養毛効果を発揮し得る養毛剤に関する。
【0002】
さらに詳しくは、アミノ酸,高級脂肪酸及び高級アルコールより選択される1種又は2種以上を含有する脂質二分子膜に、育毛,養毛効果を有する成分を内包させて配合することを特徴とする、養毛剤に関する。
【0003】
【従来の技術】
脱毛症は、栄養摂取不良,ふけの過剰発生による頭皮生理機能の低下、頭皮皮下組織,末梢血管の血流量減少に起因する毛包,毛球部の新陳代謝機能の低下、皮脂腺及び毛包,毛根部における男性ホルモンの関与による毛包機能の低下、及び精神的ストレスなど、種々多様な原因により発生する。
【0004】
かかる脱毛症を治療,改善するために、エストロン,エストラジオール,エチニルエストラジオール等の卵胞ホルモン、ビタミンE及びその誘導体,センブリ抽出物,ニンニク抽出物,ニンジン抽出物,アロエ抽出物,セファランチン,塩化カルプロニウム,ミノキシジル等の末梢血管血流促進剤、トウガラシチンキ,カンタリスチンキ,ショウキョウチンキ,ハッカ油,l−メントール,カンフル等の局所刺激剤、レゾルシン,サリチル酸,乳酸等の角質溶解剤、ピリドキシン及びその誘導体等の抗脂漏剤、ジンクピリチオン,塩化ベンザルコニウム,塩化ベンゼトニウム,クロルヘキシジン,ヒノキチオール等の殺菌剤、パントテン酸及びその誘導体,胎盤抽出物,ビオチン,ペンタデカン酸グリセリド等の毛根賦活剤、グリチルリチン酸及びその誘導体,β−グリチルレチン酸,アラントイン、アズレン,ε−アミノカプロン酸,ヒドロコルチゾン等の抗炎症剤、ビタミンA,B2,B6,B12,D等のビタミン剤、システイン,セリン,メチオニン,ロイシン,トリプトファン等のアミノ酸類などの多くの育毛,養毛成分の使用が行われてきた。
【0005】
また、主として男性型脱毛症の治療,改善を目的として、テストステロンから活性型のジヒドロテストステロンへの変換を触媒するテストステロン−5αリダクターゼの活性を阻害するものが多くスクリーニングされてきた。前記酵素の阻害剤としては、プロゲステロン,デオキシコルチコステロン等のステロイド物質の他、多種の植物の抽出物が知られている。また、オキセンドロン,スピロノラクトン,酢酸シプロテロン等はジヒドロキシテストステロンがその受容体に結合するのを阻害するといわれている。
【0006】
しかしながら、従来用いられている上記の育毛,養毛成分やテストステロン−5αリダクターゼ阻害剤の中には、副作用があるため配合可能な量が制限されたり、効果が不十分であったり、養毛剤製剤中での安定性が悪かったり、或いは一定の品質のものを得るのが困難であったりするものが多かった。
【0007】
育毛,養毛成分の安定性及び有効性を向上させるため、これらをリポソームに内包させて養毛剤に配合する試みもなされている。リポソームが毛包に選択的に到達することがすでに報告されており(Nature, Medicine, 1 (7) 705−706 (1995))、毛髪の再生促進,抜け毛減少作用を有するラブダン誘導体をリポソームに内包させて配合する技術も開示されている(特表平5−503287)。
【0008】
【発明が解決しようとする課題】
従って本発明においては、安定性及び安全性が良好で、優れた養毛効果を発揮し、且つ頭皮に対する保湿効果にも優れた養毛剤を提供することを目的とした。
【0009】
【課題を解決するための手段】
上記の課題を解決するべく種々検討を行ったところ、水分保持効果に優れるとしてすでに開示しているアミノ酸,高級脂肪酸及び高級アルコールより選択される1種又は2種以上を含有する脂質二分子膜(特開平7−285827)に、育毛,養毛効果を有する成分を内包させて配合することにより、育毛,養毛効果を有する成分の安定性及び安全性が向上し、さらに育毛,養毛効果が相乗的に増強され、しかも頭皮に対し優れた保湿効果が得られることを見い出し、本発明を完成するに至った。
【0010】
本発明において育毛,養毛成分を内包させる脂質二分子膜は、アミノ酸,高級脂肪酸及び高級アルコールより選択される1種又は2種以上を含有する。ここで、脂質二分子膜はホスファチジルコリン,ホスファチジルエタノールアミン,ホスファチジルセリン,ホスファチジルイノシトール等のグリセロリン脂質、スフィンゴミエリン等のスフィンゴリン脂質、グルコシルアシルグリセロール等のグリセロ糖脂質、ホスファチジルグルコシルアシルグリセロール等のホスホグリセロ糖脂質、グルコセレブロシド,ガラクトセレブロシド等のスフィンゴ糖脂質を用いて調製することができる。かかる脂質を80〜90℃に攪拌しながら加温溶解し、アミノ酸等の1種又は2種以上を添加して含有させる。これらの添加量は脂質二分子膜複合体の1〜20重量%が適当である。
【0011】
脂質二分子膜に含有させるアミノ酸としては、特にL−プロリン,L−イソロイシン,L−ロイシン,L−アラニン,L−スレオニン及びL−リジンより成る群から選択することが好ましい。アミノ酸を含有させた場合には、さらに水溶性高分子の1種又は2種以上を含有させてもよい。前記水溶性高分子としては、ポリアクリル酸及びその塩,カルボキシビニルポリマー及びその塩,ヒドロキシエチルセルロース,カルボキシメチルセルロース及びその塩,ヒアルロン酸及びその塩等が好ましいものとして挙げられる。これら水溶性高分子の配合量としては、脂質二分子膜複合体の0.05〜1.0重要%程度が適当である。
【0012】
また、脂質二分子膜に含有させる高級脂肪酸としては、炭素数14〜22の飽和又は不飽和脂肪酸が好ましく、高級アルコールとしては、炭素数14〜22の飽和又は不飽和脂肪族アルコールが好ましい。
【0013】
本発明において、アミノ酸等を含有する脂質二分子膜に内包させる育毛,養毛成分としては、女性ホルモンであるエストラジオール,エストロン,プロゲステロン、テストステロン−5αリダクターゼ阻害作用を有する酢酸コルチコステロン,酢酸デオキシコルチコステロン,セージ(Salvia officinalis L.)抽出物,ホップ(Humulus lupulus L.)抽出物,ローズマリー(Rosmarinus officinalis)抽出物,オトギリソウ(Hypericum erectum Thunb.)抽出物,ハッカ(Mentha arvensis L.var.piperascens Malinv.)抽出物,セイヨウハッカ(Mentha piperita L.)抽出物,カミツレ(Matricaria chamomilla L.)抽出物,アルニカ(Arnica montana L.)抽出物,タイム(Thymus vulgaris L.)抽出物、ジヒドロテストステロンの受容体への結合を阻害する作用を有するスピロノラクトン,酢酸シプロテロン,シス−ジャスモン(cis−jasmone),メチルジヒドロイソジャスモネイト(methyl dihydroisojasmonate),メチルジヒドロジャスモネイト(methyl dihydrojasmonate),ジヒドロジャスモン(dihydrojasmone)、血流促進作用を有する2,4−ジアミノ−6−ピペリジノピリミジン−3−オキシド(ミノキシジル)、毛包細胞の賦活活性を有するグリチルリチン,コウハク抽出物及びハトムギモヤシ抽出物等が好ましいものとして挙げられ、これらより1種又は2種以上を選択して用いる。なお、前記植物等の抽出物は、植物を生のままで、或いは乾燥後細切又は粉砕して、水、メタノール,エタノール,プロパノール等の低級アルコール、1,3−ブチレングリコール,プロピレングリコール,ジプロピレングリコール,グリセリン等の多価アルコール、アセトン、酢酸エチルといった極性溶媒或いはこれらの混合物を抽出溶媒として用い、浸漬等の抽出操作により得ることができる。
【0014】
育毛,養毛成分を内包させたアミノ酸等含有脂質二分子膜は、多重膜の層状(ラメラ)構造を形成させたり、球状のリポソームを形成させて養毛剤の基剤に分散させる。
【0015】
【作用】
本発明による養毛剤においては、アミノ酸等を含有する脂質二分子膜に内包された育毛,養毛成分が有効に毛包に到達し、さらに頭皮に対する保湿効果も相まって、相乗的な育毛,養毛効果の向上が認められる。
【0016】
一例として、2,4−ジアミノ−6−ピペリジノピリミジン−3−オキシド(ミノキシジル)を、プロリン及びイソロイシンを各10.0重量%含有するホスファチジルコリンリポソームに内包させ(内包率;10重量%)、ミノキシジルの最終濃度が0.2(W/V)%となるようにリン酸緩衝塩類溶液(PBS)に分散させた。このリポソーム分散液0.1mlを、除毛したマウス背部に1日1回連続して塗布し、除毛部位の色調の変化を測色した。除毛部位に発毛が見られる場合、発毛が進むにつれ測色値は低下する。実験はマウス3匹を1群として行った。結果は各群の測色値の平均値にて図1に示した。
【0017】
図1において、ミノキシジルをアミノ酸含有脂質二分子膜より成るリポソームに内包させて塗布した群(3)では、塗布開始後4週間経過後ぐらいから測色値の顕著な低下が認められ、発毛度の増加が確認された。これに対し、ミノキシジルをエタノールに溶解して塗布した群(2)では、PBSのみを塗布した対照群(1)と比べて差は認められなかった。
【0018】
さらに本発明においては、育毛,養毛成分の安定性が向上し、養毛剤への配合量も少量でよいため、副作用の発現もなく、頭皮や顔面,頸部の皮膚に対する刺激性や感作性、眼粘膜刺激性も認められない。
【0019】
【発明の実施の形態】
本発明に係る養毛剤は、ローション剤,乳剤,ゲル剤,クリーム,軟膏等の形態で提供することができ、ヘアーローション,ヘアートニック,ヘアーミルク,ヘアージェル,ヘアークリーム,ヘアーパック,ヘアートリートメント,ヘアーシャンプー,ヘアーリンスといった形態の養毛剤及び毛髪用化粧料として実施することができる。
【0020】
【実施例】
さらに本発明の特徴について、実施例により詳細に説明する。まず、各実施例において基剤に分散させた育毛,養毛成分を内包するアミノ酸等含有脂質二分子膜の調製例を表1に示した。これらは表1中の構成脂質を80〜90℃に攪拌しながら加温溶解し、アミノ酸等の添加物質を加えて混合した後冷却し、次いで育毛,養毛成分を添加し内包させて調製する。養毛剤基剤にはリポソーム又は多重膜層状物の形態として添加した。なお、表1中の構成脂質は各脂質の等重量の混合物であり、ホップ等の植物などの抽出物は50容量%エタノール溶液を用いて調製した。
【表1】
【0021】
製法:(1)〜(4)を順次(5)に添加,溶解して均一とし、次いで(6)を分散させる。
【0022】
製法:(1)〜(4)を順次(5)に添加,溶解して均一とし、次いで(6)を分散させる。
【0023】
製法:(1)〜(3)を加熱溶解し、80℃とする。一方(4)〜(9)の水相成分を混合,加熱溶解し、80℃とする。これに前記油相を攪拌しながら加え、ホモジナイザーにより均一に乳化する。冷却後30℃にて(10)を添加し、(11),(12)を分散させる。
【0024】
製法:(1)を(3)と(7)の一部に分散する。(2),(4)〜(6)を(7)の残部に溶解し、攪拌しながら前記分散物に添加する。次いで、(8),(9)を分散させる。
【0025】
製法:(4)に(1)〜(3)を加えて均一に溶解する。一方、(5)〜(7)の水相を混合,溶解し、前記溶液に加えて混合して均一とし、次いで(8)を分散させる。
【0026】
製法:(1)〜(5)を混合し、均一に溶解する。一方、(6)を(7)に溶解し、前記アルコール相に加え、ろ過した後(8)を分散させる。
【0027】
製法:(1)を(2)と(8)の一部に分散する。(3)〜(7)を(8)の残部に溶解し、攪拌しながら前記分散物に添加する。次いで、(9),(10)を分散させる。
【0028】
製法:(3)を(2)と(4)の溶解物に添加し、ホモミキサーで均一に乳化する。これを(1),(5)〜(7)の溶液に添加した後、(8),(9)を分散させる。充填は缶に原液を充填し、バルブ装着後液化石油ガスを充填する。
【0029】
製法:(9)を70℃に加熱し、(1)〜(8)を加え均一に溶解した後冷却し(10)〜(12)を分散させる。
【0030】
製法:(5)〜(9)の水相成分を混合,溶解して70℃に加熱する。一方(1)〜(4)の油相成分を混合し、70℃に加熱する。前記水相に油相を添加してホモミキサーにて乳化し、冷却後(10)〜(12)を分散させる。
【0031】
上記本発明の実施例のうち、実施例1〜実施例4について毛髪の成長促進効果の評価を行った。各実施例において、育毛,養毛成分をそれぞれアミノ酸等を含有する脂質二分子膜に内包させずに配合し、全量を精製水で100重量%としたものをそれぞれ比較例1〜比較例4とし、男性型脱毛症患者における使用試験を行った。使用試験は男性型脱毛症患者20名を1群とし、各群に実施例及び比較例をそれぞれブラインドにて1日2回、6カ月間連続使用させ、6カ月後の発毛の程度を写真撮影により評価して行った。評価は表2に示す判定基準に従って行い、各評価点数を得たパネラー数にて表3に示した。
【表2】
【0032】
【表3】
表3において、本発明の実施例使用群では、ほとんどのパネラーで全体的な生毛が認められ、45%以上ののパネラーで硬毛の発生が見られる等、いずれも良好な発毛状況が認められる。これに対して、育毛,養毛成分をアミノ酸等を含有する脂質二分子膜に内包させないで配合した比較例使用群では、いずれも対応する実施例使用群に比べ発毛の程度は低く、比較例1及び比較例2使用群では、硬毛の発生を認めたパネラーは見られなかった。
【0033】
なお上記の使用試験期間中において、実施例1〜実施例4のいずれにおいても製剤の変質や状態の悪化は見られず、各実施例を使用したパネラーにおいても、紅斑や浮腫の発生といった皮膚刺激反応や、皮膚感作性反応は全く認められなかった。
【0034】
次いで、本発明の実施例5〜実施例10について使用試験を行った。この際にも、各実施例において育毛,養毛成分をアミノ酸等を含有する脂質二分子膜に内包しないで配合し、全量を精製水で100重量%としたものを比較例5〜比較例10とした。使用試験は薄毛の気になる男女パネラー20名を1群とし、1日2回、6カ月間連続して使用させ、薄毛の改善状況,使用時のしっとり感及び使用時の刺激感,不快感の有無について官能評価させて行った。官能評価結果は、薄毛の改善状況については、「改善された;5点」,「やや改善された;4点」,「変化なし;3点」,「やや悪化した;2点」,「悪化した;1点」、使用時のしっとり感については「ある;5点」,「ややある;4点」,「どちらともいえない;3点」,「ややない;2点」,「ない;1点」として点数化し、20名の平均値を求めた。使用時の刺激感及び不快感については、表4に示す判定基準に従って評価させ、20名の平均値を求め、刺激指数とした。結果は表5にまとめて示した。
【表4】
【0035】
【表5】
表5において明らかなように、本発明の実施例使用群では、育毛,養毛成分の含有量が少ないにもかかわらず薄毛症状の改善傾向が認められている。これに対し、育毛,養毛成分をアミノ酸等を含有する脂質二分子膜に内包させないで配合した比較例使用群では、いずれにおいてもはっきりした改善は認められていなかった。また使用時のしっとり感について、本発明の実施例使用群では、いずれにおいてもそれぞれ対応する比較例使用群に比べて有意に高い評価を得ていた。さらに、いずれの実施例使用群においても特に問題となる刺激感及び不快感は認められておらず、特に実施例7〜実施例10使用群では、比較例7〜比較例10使用群に比べて有意に低い刺激指数を示していた。
【0036】
なお上記の使用試験期間中において、実施例5〜実施例10のいずれにおいても製剤の変質や状態の悪化は見られず、各実施例を使用したパネラーにおいても、紅斑や浮腫の発生といった皮膚刺激反応や、皮膚感作性反応は全く認められなかった。
【0037】
【発明の効果】
以上詳述したように、本発明により、安定性及び安全性が良好で、優れた養毛効果を発揮し、且つ頭皮に対する保湿効果にも優れた養毛剤を提供することができた。
【図面の簡単な説明】
【図1】2,4−ジアミノ−6−ピペリジノピリミジン−3−オキシド(ミノキシジル)を、アミノ酸を含有する脂質二分子膜にてリポソーム化して塗布した場合と、エタノールに溶解して塗布した場合の発毛のようすを示す図である。
【符号の説明】
1 対照群
2 ミノキシジルのエタノール溶液塗布群
3 ミノキシジル内包リポソーム塗布群[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention is to replenish water to the scalp with good water retention, or to control water evaporation from the scalp, and to allow components having hair growth and hair growth effects to reach the hair follicle selectively and efficiently. Accordingly, the present invention relates to a hair restorer capable of protecting the scalp from drying, relieving symptoms such as dandruff and itch caused by drying of the scalp, and exhibiting excellent hair growth and hair growth effects.
[0002]
More specifically, it is characterized in that a lipid bilayer containing one or more selected from amino acids, higher fatty acids and higher alcohols is incorporated with a component having a hair-growth and hair-growth effect, and is blended. Related to hair restorer.
[0003]
[Prior art]
Alopecia is caused by poor nutrition intake, decreased scalp physiological function due to excessive dandruff, hair follicles caused by decreased blood flow in the scalp subcutaneous tissue and peripheral blood vessels, decreased metabolic function in the hair bulb, sebaceous glands and hair follicles, hair roots It is caused by a variety of causes, such as reduced hair follicle function due to the involvement of androgens in the head and mental stress.
[0004]
In order to treat and improve such alopecia, estrogen such as estrone, estradiol, ethinyl estradiol, vitamin E and its derivatives, assembly extract, garlic extract, carrot extract, aloe extract, cepharanthin, carpronium chloride, minoxidil And other peripheral stimulating agents such as pepper tincture, tincture tincture, ginger tincture, peppermint oil, l-menthol, camphor, etc., keratolytic agents such as resorcin, salicylic acid, lactic acid, pyridoxine and derivatives thereof. Antiseborrheic agents, fungicides such as zinc pyrithione, benzalkonium chloride, benzethonium chloride, chlorhexidine, hinokitiol, pantothenic acid and its derivatives, placental extracts, hair root activators such as biotin and pentadecanoic acid glyceride, glycyrrhizin And its derivatives, beta-glycyrrhetinic acid, allantoin, azulene, .epsilon.-aminocaproic acid, anti-inflammatory agents such as hydrocortisone, vitamin A, B 2, B 6, B 12, vitamin agents such as D, cysteine, serine, methionine, leucine Many hair growth and hair growth components such as amino acids such as tryptophan and the like have been used.
[0005]
In addition, for the purpose of treating and improving male pattern baldness, many screenings have been screened for those that inhibit the activity of testosterone-5α reductase, which catalyzes the conversion of testosterone to active dihydrotestosterone. Known inhibitors of the enzyme include steroid substances such as progesterone and deoxycorticosterone, as well as various plant extracts. Also, oxendrone, spironolactone, cyproterone acetate and the like are said to inhibit dihydroxytestosterone from binding to its receptor.
[0006]
However, some of the conventionally used hair growth and hair growth components and testosterone-5α reductase inhibitors have side effects, so that the amount that can be incorporated is limited, the effect is insufficient, In many cases, the stability at the time was poor, or it was difficult to obtain a product of a certain quality.
[0007]
In order to improve the stability and effectiveness of hair growth and hair growth components, attempts have been made to incorporate them into liposomes and blend them into hair growth agents. It has already been reported that liposomes selectively reach hair follicles (Nature, Medicine, 1 (7) 705-706 (1995)), and liposome encapsulation of a labdone derivative having an action of promoting hair regeneration and reducing hair loss. A technique of blending by blending is also disclosed (Japanese Patent Publication No. 5-503287).
[0008]
[Problems to be solved by the invention]
Accordingly, an object of the present invention is to provide a hair restorer having good stability and safety, exhibiting an excellent hair restore effect, and also having an excellent moisturizing effect on the scalp.
[0009]
[Means for Solving the Problems]
Various studies have been made to solve the above-mentioned problems. As a result, a lipid bilayer membrane containing one or two or more selected from amino acids, higher fatty acids and higher alcohols already disclosed as having excellent water retention effect ( Japanese Patent Application Laid-Open No. 7-285827) incorporates a component having a hair-growth and hair-growth effect, and mixes it, thereby improving the stability and safety of the component having a hair-growth and hair-growth effect, and further improving the hair growth and hair-growth effect. The inventors have found that synergistically enhanced and an excellent moisturizing effect on the scalp can be obtained, thereby completing the present invention.
[0010]
In the present invention, the lipid bilayer membrane encapsulating hair growth and hair growth components contains one or more selected from amino acids, higher fatty acids and higher alcohols. Here, the lipid bilayer is composed of glycerophospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingolipids such as sphingomyelin, glyceroglycolipids such as glucosylacylglycerol, and phosphoglyceroglycolipids such as phosphatidylglucosylacylglycerol. And glycosphingolipids such as glucocerebroside and galactocerebroside. The lipid is heated and dissolved at 80 to 90 ° C. with stirring, and one or more amino acids and the like are added and contained. The appropriate amount of these additives is 1 to 20% by weight of the lipid bilayer complex.
[0011]
The amino acid to be contained in the lipid bilayer is preferably selected from the group consisting of L-proline, L-isoleucine, L-leucine, L-alanine, L-threonine and L-lysine. When an amino acid is contained, one or more water-soluble polymers may be further contained. Preferred examples of the water-soluble polymer include polyacrylic acid and salts thereof, carboxyvinyl polymer and salts thereof, hydroxyethyl cellulose, carboxymethyl cellulose and salts thereof, and hyaluronic acid and salts thereof. A suitable amount of these water-soluble polymers is about 0.05 to 1.0% by weight of the lipid bilayer membrane complex.
[0012]
The higher fatty acid contained in the lipid bilayer is preferably a saturated or unsaturated fatty acid having 14 to 22 carbon atoms, and the higher alcohol is preferably a saturated or unsaturated aliphatic alcohol having 14 to 22 carbon atoms.
[0013]
In the present invention, the hair growth and hair growth components to be encapsulated in a lipid bilayer containing an amino acid or the like are estradiol, estrone, progesterone, and testosterone-5α reductase, which are female hormones. Kosuteron, sage (Salvia officinalis L.) extract, hop (Humulus lupulus L.) extracts, rosemary (Rosmarinus officinalis) extract, St. John's wort (Hypericum erectum Thunb.) extract, peppermint (mentha arvensis L.var. piperascens Malinv.) extract, peppermint (mentha piperita L.) extract, chamomile (M tricaria chamomilla L.) extract, arnica (Arnica montana L.) extract, thyme (Thymus vulgaris L.) extract, spironolactone having the effect of inhibiting the binding of dihydrotestosterone receptors, cyproterone acetate, cis - jasmone (Cis-jasmone), methyldihydroisojasmonate, methyldihydrojasmonate, dihydrojasmone, dihydrojasmone, 2,4-diamino having a blood flow promoting action Pyrimidine-3-oxide (minoxidil), glycyrrhizin having hair follicle cell activating activity, amber extract Fine pearl barley sprouts extract and the like as preferred, selected and used one or more from these. The extract of the plant or the like may be obtained by cutting the plant as it is, or by drying and then shredding or pulverizing the same into water, lower alcohols such as methanol, ethanol, and propanol, 1,3-butylene glycol, propylene glycol, A polar solvent such as polyhydric alcohols such as propylene glycol and glycerin, acetone and ethyl acetate, or a mixture thereof can be used as an extraction solvent and can be obtained by an extraction operation such as immersion.
[0014]
The lipid bilayer containing amino acids and the like containing hair growth and hair growth components forms a multilamellar (lamella) structure or forms spherical liposomes and is dispersed in a hair growth agent base.
[0015]
[Action]
In the hair restorer according to the present invention, the hair-growth and hair-growth components contained in the lipid bilayer containing amino acids and the like effectively reach the hair follicle, and further have a moisturizing effect on the scalp, so that a synergistic hair-growth and hair-growth effect is obtained. Improvement is recognized.
[0016]
As an example, 2,4-diamino-6-piperidinopyrimidine-3-oxide (minoxidil) is encapsulated in phosphatidylcholine liposomes each containing 10.0% by weight of proline and isoleucine (encapsulation rate: 10% by weight), Minoxidil was dispersed in phosphate buffered saline (PBS) so that the final concentration of minoxidil was 0.2 (W / V)%. 0.1 ml of this liposome dispersion was continuously applied to the back of the hair-removed mouse once a day, and the color change of the hair-removal site was measured. When hair growth is observed at the hair removal site, the colorimetric value decreases as hair growth proceeds. The experiment was performed with three mice as one group. The results are shown in FIG. 1 as the average of the colorimetric values of each group.
[0017]
In FIG. 1, in the group (3) in which minoxidil was encapsulated in a liposome comprising an amino acid-containing lipid bilayer and applied, a remarkable decrease in the colorimetric value was observed about 4 weeks after the start of application, and the hair growth degree was observed. Increase was confirmed. In contrast, no difference was observed in the group (2) to which minoxidil was dissolved in ethanol and applied, as compared to the control group (1) to which only PBS was applied.
[0018]
Furthermore, in the present invention, the stability of the hair growth and hair growth components is improved, and the amount of the hair growth agent to be used may be small, so that there are no side effects, irritation and sensitization to the skin of the scalp, face and neck. No mucosal irritation was observed.
[0019]
BEST MODE FOR CARRYING OUT THE INVENTION
The hair restorer according to the present invention can be provided in the form of a lotion, an emulsion, a gel, a cream, an ointment and the like, and includes a hair lotion, a hair tonic, a hair milk, a hair gel, a hair cream, a hair pack, a hair treatment, and a hair. It can be implemented as a hair restorer in the form of a shampoo or a hair rinse and a hair cosmetic.
[0020]
【Example】
Further, features of the present invention will be described in detail with reference to examples. First, Table 1 shows examples of preparation of a lipid bilayer containing amino acids and the like containing hair growth and hair growth components dispersed in a base material in each Example. These are prepared by heating and dissolving the constituent lipids in Table 1 while stirring at 80 to 90 ° C., adding and mixing additional substances such as amino acids, cooling, and then adding and growing hair growth and hair growth ingredients. . The hair restorer base was added in the form of liposomes or multilamellar materials. The constituent lipids in Table 1 were a mixture of equal weights of each lipid, and extracts of plants such as hops were prepared using a 50% by volume ethanol solution.
[Table 1]
[0021]
Production method: (1) to (4) are sequentially added to (5) and dissolved to make uniform, and then (6) is dispersed.
[0022]
Production method: (1) to (4) are sequentially added to (5) and dissolved to make uniform, and then (6) is dispersed.
[0023]
Production method: (1) to (3) are heated and melted to 80 ° C. On the other hand, the aqueous phase components (4) to (9) are mixed and dissolved by heating to 80 ° C. The oil phase is added thereto with stirring, and the mixture is uniformly emulsified by a homogenizer. After cooling, (10) is added at 30 ° C. to disperse (11) and (12).
[0024]
Production method: (1) is dispersed in a part of (3) and (7). (2), (4) to (6) are dissolved in the remainder of (7) and added to the dispersion while stirring. Next, (8) and (9) are dispersed.
[0025]
Production method: (1) to (3) are added to (4) and uniformly dissolved. On the other hand, the aqueous phases (5) to (7) are mixed and dissolved, added to the solution and mixed to make the mixture uniform, and then (8) is dispersed.
[0026]
Production method: (1) to (5) are mixed and uniformly dissolved. On the other hand, (6) is dissolved in (7), added to the alcohol phase, filtered, and (8) is dispersed.
[0027]
Production method: (1) is dispersed in a part of (2) and (8). (3) to (7) are dissolved in the remainder of (8) and added to the dispersion while stirring. Next, (9) and (10) are dispersed.
[0028]
Production method: (3) is added to the melts of (2) and (4) and emulsified uniformly with a homomixer. After this is added to the solutions (1), (5) to (7), (8) and (9) are dispersed. For filling, a can is filled with a stock solution, and after mounting a valve, liquefied petroleum gas is filled.
[0029]
Manufacturing method: (9) is heated to 70 ° C., (1) to (8) are added and uniformly dissolved, and then cooled to disperse (10) to (12).
[0030]
Production method: The aqueous phase components (5) to (9) are mixed and dissolved and heated to 70 ° C. On the other hand, the oil phase components (1) to (4) are mixed and heated to 70 ° C. The oil phase is added to the water phase, emulsified by a homomixer, and after cooling, (10) to (12) are dispersed.
[0031]
Of the above examples of the present invention, the effects of promoting hair growth were evaluated for Examples 1 to 4. In each example, hair growth and hair growth components were blended without encapsulation in a lipid bilayer containing amino acids and the like, respectively, and the total amount was adjusted to 100% by weight with purified water, as Comparative Examples 1 to 4, respectively. And a use test in male pattern baldness patients. In the use test, 20 male alopecia patients were grouped into one group, and each group was allowed to use the examples and comparative examples twice a day for 6 months consecutively with a blind, and photographed the degree of hair growth after 6 months. The evaluation was performed by photographing. The evaluation was performed according to the criteria shown in Table 2, and the number of panelists who obtained each evaluation score is shown in Table 3.
[Table 2]
[0032]
[Table 3]
In Table 3, in the group using the examples of the present invention, overall hair growth was observed in most of the panelists, and hard hair was observed in 45% or more of the panelists. Is recognized. On the other hand, in the comparative group using the hair growth and hair growth components without encapsulating them in the lipid bilayer containing amino acids, the degree of hair growth was lower than in the corresponding group using the examples. In the group using Example 1 and Comparative Example 2, there was no paneler who observed the generation of hard hair.
[0033]
During the above-mentioned use test period, no deterioration or deterioration of the preparation was observed in any of Examples 1 to 4, and skin irritation such as occurrence of erythema and edema was observed in panelists using each Example. No reaction or skin sensitization reaction was observed.
[0034]
Next, use tests were performed on Examples 5 to 10 of the present invention. Also in this case, in each of Examples, hair growth and hair growth components were blended without encapsulation in a lipid bilayer containing amino acids and the like, and the total amount was adjusted to 100% by weight with purified water. And In the use test, 20 male and female panelists who are worried about thinning hair are used as a group twice a day for 6 consecutive months, and the improvement of thinning hair, moist feeling at the time of use, irritation at the time of use, and discomfort during use The presence / absence was evaluated by sensory evaluation. The results of the sensory evaluation were as follows: Regarding the improvement status of the thin hair, "Improved; 5 points", "Slightly improved; 4 points", "No change; 3 points", "Slightly worse; 2 points", "Worse" 1 point, and the moist feeling during use was "5 points", "Somewhat; 4 points", "Neither; 3 points", "Slightly low; 2 points", "No;1" The points were scored as "points", and the average value of 20 persons was obtained. The irritation and discomfort during use were evaluated according to the criteria shown in Table 4, and the average value of the 20 subjects was determined and used as the irritation index. The results are summarized in Table 5.
[Table 4]
[0035]
[Table 5]
As is evident from Table 5, in the group using the examples of the present invention, the tendency of improving the hair thinning symptom is recognized despite the low content of the hair growth and hair growth components. On the other hand, no clear improvement was observed in any of the comparative example groups in which the hair growth and hair growth components were blended without being encapsulated in the lipid bilayer containing amino acids and the like. In addition, the moist feeling during use was significantly higher in the group using the example of the present invention than in the corresponding group using the comparative example. Furthermore, no irritating sensation and discomfort, which are particularly problematic, were observed in any of the groups using Examples, and particularly in the groups using Examples 7 to 10, compared with the groups using Comparative Examples 7 to 10. It showed a significantly lower stimulation index.
[0036]
During the above use test period, no deterioration or deterioration of the preparation was observed in any of Examples 5 to 10, and even in the panel using each Example, skin irritation such as erythema and edema occurred. No reaction or skin sensitization reaction was observed.
[0037]
【The invention's effect】
As described in detail above, according to the present invention, it was possible to provide a hair restorer having good stability and safety, exhibiting an excellent hair restore effect, and also having an excellent moisturizing effect on the scalp.
[Brief description of the drawings]
FIG. 1 shows a case where 2,4-diamino-6-piperidinopyrimidine-3-oxide (minoxidil) is applied in the form of a liposome using a lipid bilayer membrane containing an amino acid, and a case where it is dissolved in ethanol and applied. It is a figure which shows the state of hair growth in the case.
[Explanation of symbols]
1
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23260996A JP3596835B2 (en) | 1996-08-13 | 1996-08-13 | Hair restorer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23260996A JP3596835B2 (en) | 1996-08-13 | 1996-08-13 | Hair restorer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH1059829A JPH1059829A (en) | 1998-03-03 |
| JP3596835B2 true JP3596835B2 (en) | 2004-12-02 |
Family
ID=16942036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23260996A Expired - Fee Related JP3596835B2 (en) | 1996-08-13 | 1996-08-13 | Hair restorer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3596835B2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704050D0 (en) * | 1997-02-27 | 1997-04-16 | Unilever Plc | Hair treatment composition |
| GB9912085D0 (en) * | 1999-05-24 | 1999-07-21 | Unilever Plc | Use of amino acids in hair treatment |
| WO2002056849A1 (en) * | 2001-01-17 | 2002-07-25 | Biotech Inc. | Hair growth stimulants |
| NL1018637C2 (en) * | 2001-07-26 | 2003-01-28 | Adriaan Emanuel Hendricus Wiel | Cosmetic application of hops and choline and / or cystine. |
| DE10243626A1 (en) * | 2002-09-19 | 2004-04-01 | Henkel Kgaa | Hair treatment composition containing an active ingredient combination with liposomes |
| US20040185075A1 (en) | 2003-01-31 | 2004-09-23 | Maria Dalko | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin |
| FR2850571B1 (en) * | 2003-01-31 | 2006-07-07 | Oreal | USE OF A JASMONIC ACID (DIHYDRO) DERIVATIVE FOR THE TREATMENT OF DRY SKINS |
| BRPI0804172A2 (en) * | 2008-07-15 | 2010-07-06 | Pereira Lopes Jose Emilio Fehr | chemical compounds formed from nanocapsulations and element complexation |
| PL2344198T3 (en) * | 2008-09-27 | 2021-05-31 | Jina Pharmaceuticals Inc. | Lipid based pharmaceutical preparations for topical application |
| US9505820B2 (en) | 2010-09-01 | 2016-11-29 | Zotos International, Inc. | Hair treatment composition with naturally - derived peptide identical to human hair |
| JP5885186B2 (en) * | 2011-05-19 | 2016-03-15 | 株式会社ミルボン | Cosmetic composition for scalp |
| US8883220B2 (en) | 2011-09-16 | 2014-11-11 | Nanocare Technologies, Inc. | Compositions of jasmonate compounds |
| JP6097901B2 (en) * | 2012-03-01 | 2017-03-22 | 株式会社サイエンスリン | Testosterone 5α-reductase activity inhibitor |
| BR112017014229A2 (en) | 2014-12-31 | 2018-03-06 | Nanocare Technologies, Inc. | conjugate, composition, and method for treating a disorder. |
| WO2017159922A1 (en) | 2016-03-18 | 2017-09-21 | (주)케어젠 | Conjugate of finasteride with peptide |
-
1996
- 1996-08-13 JP JP23260996A patent/JP3596835B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH1059829A (en) | 1998-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3596835B2 (en) | Hair restorer | |
| CN102159179B (en) | Composition for prevention and treatment of alopecia or for hair growth | |
| MXPA00001000A (en) | A hair lotion with improved properties in its hair protecting action and prevention of hair loss, and the reduction of external effects of androgenic alopecia and resulting hair loss. | |
| JP3597210B2 (en) | Hair restoration | |
| KR102302131B1 (en) | Composition for hair tonic or treating or preventing hair loss | |
| JPH11269043A (en) | Cosmetic for scalp and hair | |
| JPH11269042A (en) | Cosmetic for scalp and hair | |
| JPH0853327A (en) | Hair tonic composed of allantoin or its derivative | |
| JPS6156118A (en) | Hair growing cosmetic | |
| JP2001288046A (en) | Composition for scalp and hair | |
| JP3045613B2 (en) | Hair restoration cosmetics | |
| JPH09241137A (en) | Hair crowing and restoring agent | |
| JP2546813B2 (en) | Hair nourishing cosmetics | |
| JPS61171413A (en) | Hair tonic | |
| JP3382148B2 (en) | External preparation for head | |
| JPH11302133A (en) | Cosmetic for scalp and hair | |
| JPH11255621A (en) | Cosmetic for scalp and hair | |
| JP2774071B2 (en) | Hair restoration cosmetics | |
| JP2004026812A (en) | Hair restoration | |
| JPH10273424A (en) | Cosmetic for hair | |
| JPH1017440A (en) | Hair growing and restoring agent | |
| JPH0640858A (en) | Hair tonic | |
| JPH11263714A (en) | Cosmetic for scalp and hair of head | |
| JP3717676B2 (en) | Hair nourishing | |
| JPH0248512A (en) | Hair tonic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040610 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040809 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040902 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040906 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070917 Year of fee payment: 3 |
|
| RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D05 |
|
| LAPS | Cancellation because of no payment of annual fees |